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Abstract
It has been difficult to find robust brain structural correlates of the overall severity of major depressive disorder (MDD).
We hypothesized that specific symptoms may better reveal correlates and investigated this for the severity of
insomnia, both a key symptom and a modifiable major risk factor of MDD. Cortical thickness, surface area and
subcortical volumes were assessed from T1-weighted brain magnetic resonance imaging (MRI) scans of 1053 MDD
patients (age range 13-79 years) from 15 cohorts within the ENIGMA MDD Working Group. Insomnia severity was
measured by summing the insomnia items of the Hamilton Depression Rating Scale (HDRS). Symptom specificity was
evaluated with correlates of overall depression severity. Disease specificity was evaluated in two independent samples
comprising 2108 healthy controls, and in 260 clinical controls with bipolar disorder. Results showed that MDD patients
with more severe insomnia had a smaller cortical surface area, mostly driven by the right insula, left inferior frontal
gyrus pars triangularis, left frontal pole, right superior parietal cortex, right medial orbitofrontal cortex, and right
supramarginal gyrus. Associations were specific for insomnia severity, and were not found for overall depression
severity. Associations were also specific to MDD; healthy controls and clinical controls showed differential insomnia
severity association profiles. The findings indicate that MDD patients with more severe insomnia show smaller surfaces
in several frontoparietal cortical areas. While explained variance remains small, symptom-specific associations could
bring us closer to clues on underlying biological phenomena of MDD.
Introduction
Multiple findings highlight the importance of insomnia
for psychiatric disorders in general, and in particular for
major depressive disorder (MDD)1. Insomnia is a primary
risk factor for developing MDD, e.g., ref. 2, and its presence
in people suffering fromMDD hampers the effectiveness of
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clinical interventions, e.g., ref. 3. Treating insomnia can also
improve the outcome of patients suffering from depres-
sion4,5. Moreover, recent genome-wide association studies
report a strong genetic correlation between insomnia and
depressive symptoms and MDD6,7. Given these findings, it
seems highly relevant to identify neural correlates of
insomnia severity in people suffering from MDD.
To date, brain structural correlates of insomnia symptoms
in people with MDD are largely unexplored. Elucidating such
correlates may provide key clues to ultimately uncovering the
neural correlates of the risk for MDD development. Several
anatomical magnetic resonance imaging studies compared
people with insomnia disorder (ID) without MDD to those
without sleep complaints. People with ID reported smaller
gray matter (GM) volumes in the orbitofrontal (OFC)8–10,
parietal8 as well as middle cingulate11 cortices, the pineal
gland12, the thalamus13, and a smaller volume and surface
area in the inferior frontal gyrus pars triangularis14, as well as
a larger GM volume in the rostral anterior cingulate cortex
(rACC)9. Some studies have suggested a smaller hippo-
campal volume in people with insomnia15,16, but these
findings could not be replicated, e.g., refs. 8–10,17. Other
studies in people with ID assessed cortical thickness and
found a thinner cortex in the ACC, precentral and lateral
prefrontal cortex18 and a thicker cortex in several OFC
regions, the rACC, middle cingulate cortex, insula, superior
parietal cortex, and fusiform area19. In MDD patients, brain
structural correlates of insomnia severity have hardly been
investigated. A larger amygdala and smaller medial OFC
have been reported in MDD patients with insomnia20,21 as
compared to MDD patients without insomnia.
It is tempting to presume that brain areas involved in the
severity of insomnia in people without MDD are also
involved in the severity of insomnia in people suffering from
MDD. However, the complexity of the neuronal networks
involved in sleep regulation and MDD makes it also con-
ceivable that different brain mechanisms can underlie see-
mingly similar sleep complaints22,23. The present study
therefore applied a whole-brain analysis to uncover brain
structural correlates of insomnia severity in people diag-
nosed with MDD. We evaluated, in a sample of 1053 MDD
patients, whether insomnia severity was associated with
global and regional differences in cortical thickness, cortical
surface areas, and volumes of subcortical regions. Addi-
tionally, we evaluated whether the identified associations: (1)
were specific to insomnia or driven by overall depression
severity and (2) specific to MDD or also present in healthy
controls (n= 2108) and clinical controls with bipolar dis-
order (BD; n= 260).
Materials and methods
Samples
Data for the main analysis were assembled from 15
independent samples of the ENIGMA (Enhancing
NeuroImaging Genetics through Mega-Analysis) MDD
working group (http://enigma.ini.usc.edu/). We included
1053 people who met criteria for current MDD and had
completed the Hamilton Depression Rating Scale
(HDRS)24. Supplementary Table S1 lists the diagnostic
instruments and the exclusion criteria applied at each of
the 15 participating sites. Additional data from clinical
controls and healthy controls were assembled to evaluate
whether insomnia associations were specific to MDD (see
Supplementary Methods for details). For clinical controls,
we were able to include 260 patients from 5 ENIGMA BD
working group sites in whom the HDRS had been asses-
sed (see Supplementary Table S2 for demographics). Next
to a first healthy control sample of ENIGMA (n= 1277
completed the HDRS), we evaluated associations in a
second healthy control sample from the Human Con-
nectome Project (HCP)25 of which n= 831 had completed
the Pittsburgh Sleep Quality Index (PSQI)26 (see Supple-
mentary Table S3 for demographics). Exclusion criteria
for healthy controls were a history of MDD, a current
diagnosis of MDD, or any other psychiatric disorders. All
sites obtained approval from local institutional review
boards and ethics committees. All participants provided
informed consent.
Severity of insomnia and overall depression severity
Three HDRS items were summed to obtain a valid
insomnia severity score27 and the remaining items for an
insomnia-independent depression severity score, here refer-
red to as the HDRS-14 (Supplementary Methods). In the
second healthy control sample (HCP), corresponding PSQI
items were summed to obtain an insomnia severity score and
an insomnia-independent depression severity score was cal-
culated by excluding the sleep item from the total depression
score of the Achenbach Adult Self Report questionnaire28.
Supplementary Methods provide details and validation.
Image processing and analysis
Image acquisition parameters for each site are provided
in Supplementary Table S4. Schmaal et al. and Glasser
et al.29–31 provide details of the use of FreeSurfer32 seg-
mentation to obtain surface area and thickness of 68
cortical regions33, as well as 14 subcortical volumes, lat-
eral ventricle volumes, 2 whole-hemisphere measures, and
intracranial volume (ICV).
Statistical analyses
MDD patients
Linear mixed-effects models regressed insomnia severity
on surface and thickness of cortical regions and subcortical
volume. First, we evaluated whether insomnia severity could
be predicted from the overall cortical surface area, its aver-
age thickness, or from total subcortical volume. Separate
models subsequently evaluated individual brain regions.
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Models were adjusted for age, sex, scanner site (random
intercept), insomnia-independent depression severity, and,
for subcortical volumes, total ICV. False discovery rate
(FDR)34 correction (p < 0.05) was applied to correct the p
values for multiple comparisons for cortical surface areas
and thickness, and subcortical volumes (respectively, 68, 68,
and 16 comparisons).
Specificity of detected associations for insomnia versus
overall depressive symptoms severity was assessed with
corresponding models with either overall HDRS-17
depression severity or the HDRS-14 insomnia-indepen-
dent depression severity as outcome.
Ancillary mixed-effects models including interaction
terms (e.g., surface area * age, surface area * sex, surface
area * antidepressant use, surface area * depression
recurrence, surface area * age of onset of depression)
investigated whether the association of insomnia severity
with cortical surface area, thickness, or subcortical
volume was modified or confounded by age, sex, the use
of antidepressant medication, depression recurrence (first
versus recurrent episode patients), or age of onset of
depression.
To obtain effect size measures for single regressors
within multivariable mixed-effects models, we calculated
Cohen’s f2 statistic. Values of 0.02, 0.15, and 0.35,
respectively, indicate a small, medium, or large effect.
The proportion of variance in insomnia severity
uniquely explained by the significant brain regions (ΔR2)
above and beyond the covariates (age, sex, HDRS-14, site,
and ICV for subcortical areas) was computed by sub-
tracting the explained variance of a model with only the
covariates from the explained variance of the full model
(brain area, age, sex, HDRS-14, site, and ICV for sub-
cortical areas) using the MuMln package in R (www.R-
project.org).
Clinical controls and healthy controls
Within each of the control samples (BD clinical controls
and healthy controls), mixed-effects analyses were repe-
ated, including the same covariates and FDR correction.
To formally evaluate whether the insomnia-related brain
associations found in MDD were similar or different
compared to each of the control samples, models
including an interaction term were additionally per-
formed, e.g., surface area * disorder (MDD versus BD).
Interaction analyses may lack power and require a larger
sample size35. Therefore, it was additionally evaluated
whether adding controls to the ENIGMA MDD sample
would alter the effect sizes we found in MDD patients. An
increase in effect size would support a similar or even
stronger association in controls as found in MDD. A
decrease in effect size on the contrary would suggest that
controls only add noise or have an opposite association.
Results
MDD patients
Table 1 summarizes the characteristics of the MDD
patients included at each site separately and overall.
Linear mixed-effects regression indicated more severe
insomnia in cases with a smaller total cortical surface area
(f2= 0.01, ΔR2= 0.9%, p= 0.044). Table 2, Fig. 1, and
Supplementary Fig. S1 provide the results from sub-
sequent mixed-effects regression analyses to investigate
which cortical parcels contributed most to this inverse
association. In brief, MDD patients with more severe
insomnia had smaller surface areas of the right insula
(f2= 0.02, ΔR2= 1.5%, pcorrected= 0.031), left inferior
frontal gyrus pars triangularis (f2= 0.02, ΔR2= 1.8%,
pcorrected= 0.018), the left frontal pole (f
2= 0.01, ΔR2=
0.6%, pcorrected= 0.031), right superior parietal cortex
(f2= 0.02, ΔR2= 1.6%, pcorrected= 0.026), right medial
OFC (f2= 0.02, ΔR2= 1.3%, pcorrected= 0.031), and the
right supramarginal gyrus (f2= 0.02, ΔR2= 1.3%,
pcorrected= 0.031) (Fig. 1 and Table 2). Together, these
brain regions explained 2.7% of the variance in insomnia,
above and beyond the variance explained by the covari-
ates. Models including additional covariates (anti-
depressant medication, depression recurrence, age of
onset of depression) did not change the association
between surface area and insomnia severity (see Supple-
mentary Results). Ancillary analyses showed that the
association between surface area and insomnia severity
was not modified or confounded by sex, use of anti-
depressant medication, depression recurrence, or age of
onset of depression. A significant interaction was found
between total surface area and age (p= 0.046) (see Sup-
plementary Results). The surface area regions we found
explain more variance in insomnia severity than they
explain variance in overall depression severity (see Sup-
plemental Results and Supplementary Table S5).
Insomnia severity was not associated with average (p=
0.174) or regional cortical thickness (all pcorrected > 0.574),
nor with total (p= 0.595) or local subcortical volume (all
pcorrected > 0.886; see Supplementary Tables S6 and S7).
Linear mixed-effects regression models with overall
depression severity (HDRS-17) or adjusted depression
severity (HDRS-14) as outcome measures revealed no sig-
nificant predictive value of total (all p > 0.300) or regional
surface area (all pcorrected > 0.608), nor for overall average
(all p > 0.568) or local cortical thickness (all pcorrected >
0.810), or total (p > 0.354) or local subcortical volume (all
pcorrected > 0.238).
Clinical controls and healthy controls
In BD clinical controls, insomnia severity was not sig-
nificantly associated with any of the six surface areas
found in MDD (all f2 < 0.01, p > 0.205), neither with any of
the other local surface area, thickness, or subcortical
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Table 2 Mixed effect regression analyses estimates of the association of insomnia severity with cortical surface areas
(HDRS points/cm2) in MDD patients, adjusted for age, sex, insomnia-independent depression severitya, and scanning site.
B s.e. 95% CI t-value p value FDR p value N
Left inferior frontal gyrus pars triangularis −0.10 0.03 −0.16 to −0.05 −3.66 0.000 0.018 1032
Right superior parietal cortex −0.03 0.01 −0.05 to −0.01 −3.37 0.001 0.026 1032
Left frontal pole −0.49 0.15 −0.79 to −0.19 −3.17 0.002 0.031 1051
Right medial orbitofrontal cortex −0.08 0.03 −0.13 to −0.03 −3.09 0.002 0.031 1032
Right supramarginal gyrus −0.03 0.01 −0.06 to −0.01 −3.03 0.003 0.031 969
Right insula −0.06 0.02 −0.10 to −0.02 −3.00 0.003 0.031 1019
Right inferior frontal gyrus pars triangularis −0.06 0.02 −0.11 to −0.02 −2.73 0.006 0.062 1020
Left insula −0.06 0.02 −0.10 to −0.01 −2.63 0.009 0.073 1029
Left superior parietal cortex −0.02 0.01 −0.04 to 0.00 −2.42 0.016 0.118 1027
Right frontal pole −0.29 0.12 −0.53 to −0.05 −2.36 0.018 0.124 1050
Right paracentral lobule −0.06 0.03 −0.11 to −0.01 −2.22 0.027 0.167 1046
Left entorhinal cortex −0.16 0.07 −0.30 to −0.01 −2.14 0.033 0.184 848
Right parahippocampal gyrus −0.12 0.06 −0.23 to 0.00 −2.05 0.041 0.214 1038
Left parahippocampal gyrus −0.11 0.06 −0.22 to 0.00 −1.99 0.047 0.227 1036
Right postcentral gyrus −0.02 0.01 −0.04 to 0.00 −1.95 0.052 0.234 1033
Left posterior cingulate cortex −0.06 0.03 −0.12 to 0.00 −1.92 0.055 0.234 1046
Right precentral gyrus −0.02 0.01 −0.04 to 0.00 −1.89 0.059 0.237 1043
Right inferior frontal gyrus pars opercularis −0.04 0.02 −0.09 to 0.00 −1.84 0.065 0.247 1020
Right superior frontal gyrus −0.01 0.01 −0.03 to 0.00 −1.75 0.080 0.275 1044
Left precentral gyrus −0.02 0.01 −0.04 to 0.00 −1.72 0.085 0.275 1033
Right inferior temporal gyrus −0.02 0.01 −0.04 to 0.00 −1.71 0.087 0.275 1026
Right entorhinal cortex −0.13 0.08 −0.28 to 0.02 −1.70 0.089 0.275 822
Left inferior frontal gyrus pars opercularis −0.03 0.02 −0.08 to 0.01 −1.60 0.111 0.328 1034
Right transverse temporal gyrus −0.14 0.09 −0.32 to 0.04 −1.53 0.127 0.360 1050
Right middle temporal gyrus −0.02 0.01 −0.04 to 0.01 −1.48 0.139 0.377 1007
Right fusiform gyrus −0.02 0.01 −0.05 to 0.01 −1.45 0.148 0.384 1030
Left superior frontal gyrus −0.01 0.01 −0.02 to 0.00 −1.43 0.153 0.384 1034
Left fusiform gyrus −0.02 0.01 −0.05 to 0.01 −1.41 0.158 0.385 1043
Right precuneus −0.01 0.01 −0.04 to 0.01 −1.29 0.199 0.440 1046
Left postcentral gyrus −0.01 0.01 −0.04 to 0.01 −1.25 0.213 0.440 1028
Left supramarginal gyrus −0.01 0.01 −0.04 to 0.01 −1.23 0.218 0.440 959
Left rostral anterior cingulate cortex −0.04 0.04 −0.12 to 0.03 −1.23 0.219 0.440 1032
Left inferior frontal gyrus pars orbitalis −0.08 0.07 −0.22 to 0.05 −1.22 0.224 0.440 1041
Left rostral middle frontal gyrus −0.01 0.01 −0.02 to 0.01 −1.21 0.225 0.440 1026
Left middle temporal gyrus −0.02 0.01 −0.05 to 0.01 −1.21 0.228 0.440 978
Right isthmus cingulate cortex 0.04 0.03 −0.03 to 0.11 1.19 0.233 0.440 1049
Left lingual gyrus −0.02 0.01 −0.04 to 0.01 −1.17 0.241 0.442 1045
Right temporal pole −0.10 0.09 −0.27 to 0.07 −1.15 0.252 0.443 1029
Left paracentral lobule −0.03 0.03 −0.09 to 0.02 −1.13 0.257 0.443 1047
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volume measures (all pcorrected > 0.984). To formally
evaluate whether the association between insomnia
severity and surface areas differed between MDD and BD
patients, interaction analyses were performed for each of
the six surface areas found in MDD and type of disorder
(MDD versus BD). A significant interaction effect was
found in only 2 out of the 6 surface areas (left inferior
frontal gyrus pars triangularis, p= 0.022; right supra-
marginal gyrus, p= 0.045), indicating that a smaller sur-
face in these two areas was associated with higher
insomnia severity specifically in MDD patients but not in
BD patients. When combining the BD and MDD sample
(n= 1313), the effect sizes decreased by 29–71% as
compared to the effects found for cortical surface area in
MDD only.
In the ENIGMA-MDD healthy controls, insomnia
severity was not significantly associated with any of the six
surface areas found in MDD (all f2 < 0.01, p > 0.193),
neither with any of the other global or local surface area,
thickness, or subcortical volume measures (all pcorrected >
0.441). When adding the ENIGMA healthy controls to the
MDD sample (n= 2330), the effect sizes decreased by
Table 2 continued
B s.e. 95% CI t-value p value FDR p value N
Right banks superior temporal sulcus 0.05 0.04 −0.03 to 0.13 1.12 0.263 0.443 990
Right rostral middle frontal gyrus −0.01 0.01 −0.02 to 0.01 −1.11 0.267 0.443 1030
Right lateral occipital cortex −0.01 0.01 −0.03 to 0.01 −1.05 0.295 0.478 1037
Right superior temporal gyrus −0.02 0.01 −0.04 to 0.01 −1.03 0.304 0.480 915
Left medial orbitofrontal cortex −0.02 0.02 −0.06 to 0.02 −0.97 0.332 0.513 1023
Left isthmus cingulate cortex −0.03 0.03 −0.09 to 0.03 −0.95 0.342 0.516 1043
Left lateral occipital cortex −0.01 0.01 −0.03 to 0.01 −0.94 0.350 0.517 1037
Right rostral anterior cingulate cortex −0.03 0.04 −0.11 to 0.04 −0.91 0.362 0.524 1039
Left inferior temporal gyrus −0.01 0.01 −0.03 to 0.01 −0.86 0.388 0.549 1009
Right lingual gyrus −0.01 0.01 −0.04 to 0.02 −0.81 0.420 0.580 1037
Left transverse temporal gyrus −0.06 0.07 −0.20 to 0.08 −0.80 0.427 0.580 1050
Left inferior parietal cortex −0.01 0.01 −0.02 to 0.01 −0.74 0.460 0.614 1011
Left pericalcarine cortex −0.02 0.02 −0.06 to 0.03 −0.71 0.475 0.620 1013
Left precuneus −0.01 0.01 −0.03 to 0.02 −0.69 0.491 0.620 1042
Left caudal anterior cingulate cortex −0.03 0.04 −0.10 to 0.05 −0.69 0.492 0.620 1045
Right inferior parietal cortex 0.01 0.01 −0.01 to 0.02 0.64 0.520 0.642 1019
Right caudal anterior cingulate cortex −0.02 0.03 −0.09 to 0.05 −0.61 0.542 0.650 1042
Left superior temporal gyrus −0.01 0.01 −0.04 to 0.02 −0.61 0.545 0.650 915
Right caudal middle frontal gyrus −0.01 0.01 −0.04 to 0.02 −0.59 0.555 0.651 1039
Left cuneus 0.01 0.03 −0.04 to 0.06 0.51 0.607 0.700 1010
Right inferior frontal gyrus pars orbitalis −0.02 0.06 −0.13 to 0.09 −0.34 0.736 0.834 1038
Left banks superior temporal sulcus 0.01 0.04 −0.06 to 0.08 0.31 0.755 0.842 961
Right pericalcarine cortex 0.01 0.02 −0.04 to 0.05 0.28 0.780 0.856 1010
Left caudal middle frontal gyrus 0.00 0.01 −0.03 to 0.03 −0.23 0.820 0.875 1036
Left lateral orbitofrontal cortex 0.00 0.02 −0.04 to 0.03 −0.22 0.826 0.875 1045
Right lateral orbitofrontal cortex 0.00 0.02 −0.03 to 0.04 0.21 0.836 0.875 1047
Right cuneus 0.00 0.03 −0.06 to 0.05 −0.12 0.907 0.934 1017
Right posterior cingulate cortex 0.00 0.03 −0.06 to 0.06 0.06 0.953 0.967 1048
Left temporal pole 0.00 0.09 −0.17 to 0.17 0.04 0.967 0.967 1025
MDD major depressive disorders, HDRS Hamilton Depression Rating Scale, CI confidence interval, FDR false discovery rate.
aInsomnia-independent depression severity is calculated by subtracting the insomnia scores from the total HDRS score.
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34–64% with respect to the significant effects found for
cortical surface area in MDD only. In the HCP healthy
controls, insomnia severity was only significantly asso-
ciated with 1 out of the 6 surface areas found in MDD
(right medial OFC, f2= 0.008, p= 0.009; other regions
f2 < 0.002, p > 0.188). No significant association was found
for any of the other local surface areas or for subcortical
volumes (all pcorrected > 0.089), whereas a significant
association was found for 2 out of 68 cortical thickness
regions. Healthy controls with more severe insomnia
showed a thicker right rACC (pcorrected= 0.042) and a
thinner right entorhinal cortex (pcorrected= 0.042).
Although none of six surface area by group interaction
effects reached significance (p > 0.074), interaction effects
for the two identified cortical thickness regions did (all
p < 0.016), supporting specificity for these regions to
healthy controls but not for MDD patients.
Together these results suggest differential association
profiles of cortical measures in MDD that in general do
not generalize to BD clinical controls or healthy controls.
Discussion
This large-scale study investigated brain structural corre-
lates of insomnia severity in MDD and revealed more severe
insomnia in cases with a smaller total surface area. This
inverse association with total surface area was mostly driven
by the right insula, left inferior frontal gyrus pars triangu-
laris, left frontal pole, right superior parietal cortex, right
medial OFC, and right supramarginal gyrus, that all showed
significant regional effects. The association was independent
of depression severity adjusted for the three insomnia items,
and was specific for surface area: no associations were found
for cortical thickness or subcortical volumes. The associa-
tion between surface area and insomnia severity seems
specific to MDD patients, since no associations were found
in healthy or clinical controls. Cortical surface area only
explained a small proportion of the variance in insomnia
severity, which may not be surprising, because it is con-
ceivable that a variety of other factors influence the complex
trait of insomnia. On the other hand, small effects in large
samples are more likely to be reliable and reproducible than
large effect in small samples36.
We found that surface area was specifically associated
with insomnia severity, not with overall depression
severity. Our meta-analysis29 in a large overlapping sam-
ple of adult MDD patients and controls from ENIGMA
MDD reported no significant association between cortical
surface area and depression severity measured using the
total score of the HDRS. A weak negative association was
only found between self-reported depression severity
(Beck’s Depression Inventory, BDI-II score) and surface
areas of the bilateral precuneus, left frontal pole, and left
postcentral gyrus. Our current findings indicate a better
association of total and regional surface areas for the
severity of a single-domain phenotype (insomnia symp-
toms) than for the severity of a multi-domain phenotype
(all/other mixed symptoms of depression). It should be
noted that the explained variance is still small, as is
commonly found across genetic and neuroimaging
regressors for complex traits like insomnia and depres-
sion. While the findings thus do not explain much of
individual differences, they may bring us a bit closer to
clues on underlying biological phenomena involved.
The Research Domain Criteria approach to psychiatric
disease stresses the importance of identifying fundamental
symptom dimensions tied to neural systems that cut
across heterogeneous mental disorder classifications37.
Our findings are the first to identify brain structural
correlates related to insomnia, an important clinical
symptom of the Arousal and Regulatory Systems
domain38, in people suffering from MDD. Notably how-
ever, these correlates do not seem to cut across disorders.
Our findings indicate that only cortical surface area is
predictive of insomnia severity in MDD, whereas cortical
thickness and subcortical volume had no predictive value.
Prior studies have shown that these measures represent
distinct biological processes. For example, cortical surface
area, cortical thickness, and GM volume differ in terms of
developmental trajectory39, network topology40, and
genetic influences41. As compared to cortical thickness,
-5 -4 -3 -2 -1 0 1 2 3 4 5
T-score
Lateral View Medial View
RH
LH
Fig. 1 T-scores for brain regions that show a significant (pcorrected
< 0.05) decreased surface area associated with higher insomnia
severity scores in major depressive disorder patients. Models are
adjusted for age, sex, insomnia-independent depression severity
(HDRS-14) and site. RH right hemisphere, LF left hemisphere.
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surface area is more strongly determined by genetic
influences42. To identify common genetic variants that
underlie these genetic influences on brain structures is
not straightforward, as their effects are very small. To
overcome this difficulty, >50 ENIGMA sites recently
generated a very large sample (n= 35,660) to uncover
genetic loci that affect cortical surface area and thick-
ness42. The study revealed many loci where variants were
associated with surface area. Most interestingly, genetic
correlations indicated that the variants associated with a
smaller global surface area overlapped more with the
variants involved in insomnia6 than with variants of any
other included symptom or disorder. In light of (1) the
strong genetic correlation between insomnia and cortical
surface area, (2) the genetic heritability of surface area,
and (3) the more externally driven variability of cortical
thickness, we consider it likely that overlapping neuro-
biological mechanisms predispose to both a smaller cor-
tical surface area and more severe insomnia symptoms in
MDD. We cannot fully exclude, however, the possibility
that insomnia causes a reduction of cortical surface area
as secondary process.
We found smaller surface areas of several cortical regions
to be associated with insomnia severity in MDD patients;
such associations were, however, not found in non-
depressed samples. Few studies investigated cortical sur-
face area in relation to insomnia complaints. Lim et al.43
found that sleep fragmentation was nominally associated
with lower surface area in the banks of the superior tem-
poral sulcus and pars orbitalis. While we did not find
cortical thickness to be associated with insomnia severity in
MDD, we did find insomnia severity to be associated with
thickness alterations in the entorhinal cortex and the rACC
in our healthy control sample. Several studies have repor-
ted an association between thickness and insomnia severity
in non-depressed people43–45. More specifically within
insomnia patients, one study found thinning in the ACC,
precentral cortex, and lateral prefrontal cortex18, while in
contrast another study found thickening in several areas,
including the orbital frontal cortex, rACC, middle cingulate
cortex, insula, superior parietal lobule, and fusiform area19.
Concertedly, these findings provide support for a double
dissociation suggesting a depression-specific association of
insomnia severity with cortical surface area and an asso-
ciation of insomnia severity with cortical thickness in non-
depressed people.
Reduced surface area of the medial OFC, however, was
found to be related to insomnia severity in both MDD
patients and in healthy controls in our study. One study
found reduced GM in the medial OFC in co-morbid
depression and insomnia patients compared to insomnia or
depressed patients without comorbid disorders21. Altera-
tions in the medial OFC might have a symptom-specific role
that is similar in in both insomnia and depressed patients.
The cortical regions for which a smaller surface area
predicted more severe insomnia are involved in a wide
range of functions, including emotional processing (medial
OFC, frontal pole, insula), attentional processing and
interoceptive awareness (insula), and cognitive control
(inferior frontal gyrus pars triangularis, insula, parietal
regions)46,47. It may—at first glance—be surprising that
insomnia severity is significantly associated with the surface
area of regions that are primarily involved in these pro-
cesses, while overall depression severity is not. Recent
insights, however, suggest that insomnia involves altered
emotion regulation and interoception rather than deficits
in sleep regulation per se48–50, which is again supported by
our findings of reduced surface area in regions involved in
emotional processing.
The current study has several limitations. First, we had
limited information on sleep in our sample: only three
HDRS items about insomnia. It would have been inter-
esting to evaluate whether cortical surface areas showed
similar associations with other measures of sleep, as could
be derived from sleep diaries, actigraphy, or poly-
somnography. Even so, actigraphic and polysomnographic
measures of sleep hardly correlate with the subjective
complaints that diagnostically define insomnia51. By
contrast, subjective complaints recorded in sleep diaries
strongly correlate with the insomnia items of the HDRS27.
Second, the characteristics of the HCP healthy controls
were somewhat different: they were younger, scanned on
a different scanner, and asked different insomnia ques-
tions than in the ENGIMA MDD sample. Nevertheless,
these results still provide valuable insight into how
insomnia-related brain alterations may be different in
people with MDD than in people without MDD. Third,
poor sleep quality might be associated with obstructive
sleep apnea, a late chronotype, and sleep duration. Sleep
apnea and chronotype have been associated with less
GM52 and a thinner cortex53–55; however, as far as we
know no studies have associated these variables with
cortical surface area. Insomnia severity might also be
associated with sleep duration; however, in a large study
of MDD patients the shared variance between insomnia
severity and sleep duration was limited (20%)56, suggest-
ing discernable dimensions of sleep. Unfortunately, sleep
apnea, chronotype, and sleep duration were not system-
atically assessed in our sample. It would be interesting to
evaluate whether our findings are better explained by
these variables than by quality of sleep. Lastly, other
variables could potentially have contributed to individual
differences in our dataset, such as handedness57, oral
contraceptive use58, medical comorbidities, or demen-
tia59–63. Future studies could take these variables into
account. A major strength of our study is that we obtained
data from a large representative sample of MDD patients
from 15 different sites, supporting the robustness and
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generalizability of our results. The robustness of our
findings is further supported by the lack of interaction
effects of surface area with antidepressant use, depression
recurrence, or age of onset of depression.
In conclusion, our study showed that insomnia is more
severe in patients with MDD who have a smaller cortical
surface area, in particular of the right insula, left inferior
frontal gyrus pars triangularis, left frontal pole, right
superior parietal cortex, right medial OFC, and right
supramarginal gyrus. The better specificity of these
associations with insomnia severity than with total
depression severity highlights the possibility that insom-
nia could represent a symptom cluster of MDD with a
distinct neurobiological underpinning.
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